Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Receivables (2016 - 2025)

Surgery Partners' Receivables history spans 12 years, with the latest figure at $602.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 3.99% year-over-year to $602.2 million; the TTM value through Dec 2025 reached $602.2 million, up 3.99%, while the annual FY2025 figure was $602.2 million, 3.99% up from the prior year.
  • Receivables for Q4 2025 was $602.2 million at Surgery Partners, up from $579.3 million in the prior quarter.
  • Across five years, Receivables topped out at $602.2 million in Q4 2025 and bottomed at $367.0 million in Q1 2021.
  • The 5-year median for Receivables is $459.6 million (2022), against an average of $479.3 million.
  • The largest annual shift saw Receivables grew 20.59% in 2021 before it grew 3.99% in 2025.
  • A 5-year view of Receivables shows it stood at $430.2 million in 2021, then rose by 6.07% to $456.3 million in 2022, then rose by 8.79% to $496.4 million in 2023, then rose by 16.66% to $579.1 million in 2024, then increased by 3.99% to $602.2 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Receivables are $602.2 million (Q4 2025), $579.3 million (Q3 2025), and $563.1 million (Q2 2025).